WednesdayNov 02, 2022 2:15 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Eyes Steady Growth, Traction in Distinctive Solutions

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has grown its operations with numerous improvements to its cloud-based marketplace that simplifies the once-complex process of international over-the-road (“OTR”) cross-border shipping. In addition, Fr8Tech is constantly exploring new ways to create value for its clients, streamline the region’s cross-border shipping process, and carry that over into respective domestic markets. Its efforts to date have yielded six distinctive solutions in its product suite: Fr8App, Fr8Radar, Fr8TMS, Fr8FMS, Fr8Data, and Fr8Fleet. A recent article reads, “The company’s focus on exploring new areas for revenue and value creation allowed for a 45% year-over-year (‘YOY’) revenue growth for…

Continue Reading

MondayOct 31, 2022 1:52 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

Continue Reading

MondayOct 31, 2022 1:38 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Secures LOI for up to $100M to Help Fund next Stage of Growth

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer within high-performance lidar solutions, has rapidly emerged as a leader amongst its peers – deploying its unique capabilities across a host of different environments, ranging from traffic systems in Cape Town, South Africa, to airport terminal monitoring in the U.S. “Cepton’s long-term automotive Tier 1 partner, Koito Manufacturing Co. Ltd., recently revealed that it had provided Cepton with a letter of intent representing an investment of up to $100 million to help fund Cepton’s next stage of growth as it seeks to scale its lidar solutions for mass deployment,” a recent…

Continue Reading

WednesdayOct 26, 2022 2:38 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Stands Distinct from Others in Lidar Sector

Cepton (NASDAQ: CPTN), a world-leading lidar provider, remains committed to making a potentially game-changing technology available in everyday cars, not just luxury vehicles. “The company expects lidar to benefit more consumers as the technology gets rolled out to all cars, making autonomous driving safer for all. Cepton’s partnership with world-leading automotive tier 1 supplier, Koito, a Tokyo-based manufacturer with century-long operations, marks a significant milestone on Cepton’s journey to lidar commercialization,” reads a recent article. “‘We’re working with top 10 global OEMs here in North America and Japan, and their strategies are still very much intact. So, the progress has…

Continue Reading

TuesdayOct 25, 2022 12:45 pm

TinyGemsBreaks – Freight Technologies Inc.’s (NASDAQ: FRGT) Solutions Designed to Improve Customers’ Efficiency, Profitability, Logistic Experiences

Freight Technologies (NASDAQ: FRGT), a company that develops solutions aimed at optimizing and automating the supply chain process, aims to revolutionize logistics operations for brokers, carriers and shippers by leveraging technology infrastructure to improve experiences and efficiency. “The infrastructure combines everything in a single control center, optimizing logistics, making fleets more efficient and reducing transportation costs,” reads a recent article. “Through its wholly owned subsidiary Freight App Inc. (‘Fr8App”), the company offers solutions such as the Fr8App Platform, a B2B cross-border shipping marketplace powered by artificial intelligence and machine learning; Fr8FMS, a solution that enables transportation companies and owners to…

Continue Reading

FridayOct 21, 2022 3:17 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a drug delivery platform innovator, last year announced a review of its successful 2021 antiviral drug program. “Lexaria specifically probed the bioavailability of five DehydraTECH(TM)-processed antiviral drugs for SARS-CoV-2, HIV/AIDS and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria believed, could have significant commercial potential considering that many antiviral drugs typically show low oral bioavailability in their available form because of significant liver biotransformation and/or poor intestinal uptake,” reads a recent article. “Lexaria’s vision…

Continue Reading

FridayOct 21, 2022 2:54 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Continually Upgrading Systems, Gaming Content to Maintain Competitive Edge

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, is leveraging the growth opportunity that has arisen as casino operators embrace digital avenues. “Golden Matrix’s GM-AG System is the industry standard for gaming platforms, including leading graphics and over 10,000 games to give casino operators a copious number of options and management software to keep customers happy and loyal to their brand. As a rule, casinos can’t have enough online table games, which is right in GMGI’s wheelhouse… Golden Matrix is only scratching the surface of the bounds of its potential domain. Most…

Continue Reading

WednesdayOct 19, 2022 2:13 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Anticipates Leadership Position in Alternative Cannabinoid Market Segment

Flora Growth Corp. (NASDAQ: FLGC), a global cannabis cultivator, product manufacturer and distributor, is measuring its success in rapidly rising revenues brought on by strategic acquisitions and the expanding international movement of its brands. “The company recently reported a 604% increase YoY in its H1 revenues to about $15 million, which was also a 117% increase over the previous half-year financial report, and is anticipating new momentum from the recent acquisition of the No Cap Hemp Co. brand by Flora’s wholly owned subsidiary Just Brands LLC. The No Cap acquisition is expected to add some 75 SKUs to Flora’s product…

Continue Reading

MondayOct 17, 2022 1:36 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration…

Continue Reading

MondayOct 17, 2022 1:06 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with…

Continue Reading

Contact us: (310) 299-1717